By Exec Edge Editorial Staff
SAB Biotherapeutics (Nasdaq: SABS) said it saw positive results from a Phase 3 clinical trial that assessed its Covid-19 drug, SAB-185, in non-hospitalized people who were at high-risk for severe outcomes.
SAB-185 demonstrated benefit in sustained symptom resolution in study participants with Covid-19 caused by Omicron as compared to participants who received a monoclonal antibody combination, REGEN-COV, it said in a statement.
Two-thirds of participants treated with SAB-185 reached full symptom resolution for at least four consecutive days by Day 28, while only 50% of participants on REGEN-COV met this endpoint, and the median time to symptom resolution for at least 4 consecutive days was seven days shorter for SAB-185, the company said.
The median time to symptom resolution for at least two consecutive days was six days shorter for SAB-185, as compared to those who were treated with REGEN-COV, it said.